Oral semaglutide is a daily tablet formulation of the GLP-1 (glucagon-like peptide-1) receptor agonist
den Heijer M, Blom HJ, Gerrits WBJ, Rosendaal FR, Haak HL, Wijermans PW, and Bos GMJ (1995)
Underweight individuals or those with very low BMI People who are at or below normal body weight should not use this combination
Semaglutide is a medication used to treat Type 2 diabetes by mimicking the effects of a hormone called GLP-1
External resources American Journal of Clinical Nutrition: Nutritional priorities to support GLP-1 therapy for obesity Endocrine Society: Protein may protect against muscle loss on semaglutide (ENDO 2025) Impact of semaglutide on body composition in adults with overweight or obesity: STEP 1 study For researchers serious about optimizing their peptide protocols and nutrition strategies during GLP-1 therapy, SeekPeptides offers the most comprehensive resource available, with evidence-based guides, proven protocols, personalized calculators, and a community of thousands who have navigated these exact questions
It can lower A1C from 12% to 7% in a matter of weeks